The Shift: Emeraude is the successful startup's startup
Why it matters: Baby boomers are projected to pass down between $84–$124 trillion by 2048 in the Great Wealth Transfer, so many entrepreneurs are seeing a need for family office services to help transition their assets to the next generation.
Between the lines: A family office is a structured business outside of a corporation that deals specifically with the owner's wealth and affairs, and frequently manages its philanthropy and estate planning.
State of play: They're the sort of headaches most startups covered in The Shift hope to one day have — how to grow the business, transfer it to the kids or organize governance around philanthropy.
Emeraude (the French word for emerald, but the Arkie pronunciation sounds like Emma-road) of Rogers can help do those things, aligning a family's values with its growth and legacy planning.
It isn't a wealth management or investment company, managing partner Graham Cobb told me. Emeraude will help "oversee wealth."
Case in point: Graham gave an example of a business owner wanting to build a mixed-use commercial property, but no one in the company has any particular expertise in the work involved.
"'We don't want to put it out to bid, because we're going to get gouged,'" he said of a scenario conversation. "'And we don't want to start a construction firm, and we don't want to start a property development firm.' So those are all things that family offices can do for the individual" that Emeraude can now handle.
Behind the scenes: The new company stands alone, but is chaired by Jim Smith and vice-chaired by Rebecca Hurst, who together run the Smith-Hurst law firm of Rogers.
Kristin Baldwin, chief operating officer at Smith-Hurst, also is a managing partner.
What they're saying:"We can provide accounting and financial services, personnel and office management for [an entrepreneur's] businesses, as well as their day-to-day life," he said.
"Managing some of that lifestyle concierge," like bespoke travel, Cobb said.
"Even help you understand and access emerging health services and information. These are all things that successful individuals think about and want in their lives."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Robert J. Smith, MFA Signs On For His 26th Consecutive Year Mentoring Students
He'll Create Even More; Entrepreneur Pitch Competition Champions, Polished Public Speakers, And #1 Best Selling Authors in the 2025/2026 Schoolyear A Media Snippet accompanying this announcement is available by clicking on this link. WINTER GARDEN, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Smith has helped students to excel, both in and out of school since 1999. His Entrepreneurial Pitch Competition mentees have won top cash awards in high school and medical school Finals. His work with students who compete in the annual 5th Grade Oration Competition sponsored by Modern Woodmen have helped many children overcome anxiety. His girlfriend, Sharon L. Roznowski, had one student whose parents asked that she be exempted from the competition due to 'severe anxiety.' With three weeks of work, encouragement, and proven techniques, that student not only faced her fears, she was a top ten finalist in her school. She was able to leverage that success to become a backup singer and dancer in her middle school drama program. She carried that momentum into high school where she became a lead actress and lead singer. Now, she's thriving in these roles in college. Smith is adding a new benefit for all youngsters from kindergarten through graduate school. On Liberation Day, April 2, 2025, he founded Junior Patriots™, a 501(c)(3) nonprofit to expand patriotism in American schools and turn all participating students into #1 Best Selling Authors. Becoming a #1 Best Selling Author is more than a status symbol—it's a gateway to unprecedented success. Smith Profits proven 90-day program empowers young authors create their personal brand and increase their potential, both in and out of school. They will benefit later in their careers, as #1 Best Selling Authors command higher speaking fees, become the go-to experts in their field, and gain instant authority that opens doors for television interviews and high-profile opportunities. The ripple effect of publishing a #1 Best Seller is transformative, offering a lifetime of impactful connections and profitability. The best part is that students immediately gain confidence through their achievements. This confidence increases with every advancement through their schooling and eventual careers. The gained respect and love of country, has also helped children and young adults accomplish more in school, get along better with their peers and avoid lives of trouble, despair, crime, and addiction. Smith work with America's youth is about more than short-term accomplishments, it's about learning how to succeed. In a very short amount of time, Smith teaches students important life skills that they can develop and benefit from throughout their entire lives. Students learn to get immediate results and build on their initial successes to continue to gain success. They learn to produce results that amplify their careers, enhance their credibility in those careers, and establish them as leaders in their eventual fields. This provides them with a huge edge on their eventual competition. To bring Robert J. Smith, MFA into your school or youth organization, reach out to him here or here About Robert J. Smith, MFA, Smith Profits, and Junior Patriots Robert J. Smith, MFA, known as The Father of Factual Storytelling™, has achieved #1 production rankings with multiple Fortune 500 Companies and maintains consistent top 1% worldwide rankings in the entertainment industry, after decades of consistent top 1% worldwide rankings in financial services. His international #1 Best Selling books have outranked major offerings by legends such as The Father of Systems, W. Edwards Deming; The Father of Public Relations, Edward Bernays; and The Father of Economics, Adam in 2010, Smith Profits operates from Winter Garden, Florida, specializing in business consulting, publishing, and public relations. The company provides GUARANTEED television coverage and #1 Best Selling Book services to CEOs, business owners and professionals, nationwide. Smith not only writes #1 Best Selling business books, his company, Smith Profits helps other professional boost their authority through #1 Best Selling Books, as well. Smith's 501(c)(3) Junior Patriots nonprofit's book series turns America's patriotic youth into #1 Best Selling Authors. For media inquiries, contact Smith Profits at their Winter Garden, Florida headquarters at (407) 508-0200. Press@
Business Wire
an hour ago
- Business Wire
Arcadea, Through Its Entity Vellox Group, Acquires ADSoftware in Bold Move to Disrupt Aviation Software Landscape
CLUSES, France & TORONTO & ADELAIDE, Australia--(BUSINESS WIRE)--Vellox Group, the global leader in unified aviation operations software, today announced the acquisition of ADSoftware ('ADS'), a French-based provider of CAMO and maintenance software trusted by high-criticality aviation operators around the world. 'ADSoftware exceeds every benchmark we set for our investments—founder-led, product-first, and beloved by customers.' - Paul Yancich, Managing Director at Arcadea Group Share This move expands Vellox's platform into the maintenance domain, creating an unprecedented one-stop solution for operations and airworthiness management. ADS joins Vellox's mission to deliver the industry's most comprehensive and integrated platform for aviation operators, offering unified workflows that eliminate silos between flight operations and maintenance. With ADS onboard, Vellox now covers the entire operational and maintenance lifecycle. Over 70 ADS customers will benefit from access to Vellox's global infrastructure, advanced product development resources, and 24/7 support. All ADS employees will remain in place and join Vellox, ensuring service continuity and accelerating innovation. ADS's flagship ERP, AIRPACK, will be rebranded under the Vellox umbrella as part of the unified platform strategy. 'ADSoftware is a natural fit for Vellox's disruptor vision,' said Aleksandra Banas, CEO of Vellox Group. 'Together, we're reshaping how aviation operators run their businesses from the cockpit to the hangar—with a single, integrated platform.' The acquisition strengthens Vellox's position in mission-critical aviation sectors such as EMS, defense, and industrial operations—segments that demand zero compromise on compliance, safety, and reliability. Integrating flight, crew, and maintenance data unlocks predictive analytics, smarter compliance tools, and improved operational uptime, setting new industry benchmarks. 'Joining Vellox is a major milestone. We're excited to scale globally while staying true to our roots in innovation, product excellence, and long-term customer partnerships,' said Inès Gur, Acting Managing Director of ADSoftware. The unified platform will give operators access to: Seamless workflows across planning, dispatch, safety, and maintenance A single, cohesive user experience Advanced decision support and analytics tools Elevated compliance and audit-readiness 'ADS is the missing piece that makes our platform unrivaled,' said Krister Genmark, SVP of Revenue at Vellox. "No one else offers a fully unified ecosystem for high-criticality aviation like we now do.' 'ADSoftware exceeds every benchmark we set for our investments—founder-led, product-first, and beloved by customers. We're thrilled to welcome ADS into the Vellox platform and to support its continued innovation on a global scale,' said Paul Yancich, Managing Director at Arcadea Group. For more information on Vellox Group and its innovative aviation software, visit About ADSoftware Founded in 1998 in France, ADSoftware provides modular ERP solutions for maintenance and airworthiness management. Its customers span airlines, military fleets, MRO providers, and helicopter operators. Known for reliability and regulatory depth, ADS's AIRPACK suite supports CAMO and MRO operations worldwide. About Vellox Group Vellox Group is the world's most unified aviation software platform, formed by combining Flight Vector, Spidertracks, Air Maestro, Complete Flight—and now ADSoftware. Serving emergency, defense, utility, and government operators, Vellox delivers data-rich, fully integrated tools for flight ops, dispatch, safety, crew, and maintenance. About Arcadea Group Arcadea Group is a permanent capital investor in founder-led vertical software businesses. With a long-term investment approach, Arcadea enables its companies—like Vellox—to pursue bold innovation and sustained market leadership in mission-critical sectors.
Business Wire
an hour ago
- Business Wire
CARMAT Provides an Update on the Ongoing Receivership Procedure
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today provides an update on the ongoing receivership procedure and announces the suspension of trading in CARMAT shares, starting August 14, 2025, before stock market opening, ahead of the court hearing scheduled on August 19, 2025. Update on the ongoing receivership procedure Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, the judiciary administrator had received, by the deadline of July 31, 2025, one takeover bid within the context of a sales plan (the 'Bid') 1. This Bid will be assessed by the Versailles Economic Court 2 (the "Court") at a hearing scheduled on August 19, 2025. The Company again draws attention to the fact that there is no guarantee at this stage that this Bid will be successful. The Company also reminds that even if the Bid is validated by the Court, the Company's shareholders and creditors may incur a significant loss of up to the total value of their investment or receivables. CARMAT is subject to a risk of liquidation, including in the short term. Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) Ahead of the court hearing scheduled on August 19, 2025, CARMAT has asked Euronext to suspend the trading of its shares starting on August 14, 2025, before the stock market opens. Another press release will be issued by the Company once the outcome of the court hearing is known. In any case, CARMAT endeavors to provide continuous support to patients who currently benefit from its Aeson® artificial heart. ●●● About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company is currently placed in receivership (opened on July 1, 2025) and is facing a risk of liquidation including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 Offre de reprise en plan de cession » (in French). 2 Tribunal des Activités Economiques de Versailles.
